Publications by authors named "P Meregalli"
Guideline-directed medical therapy (GDMT) has clear benefits on morbidity and mortality in patients with heart failure; however, GDMT use remains low. In the multicenter, open-label, investigator-initiated ADMINISTER trial, patients (n = 150) diagnosed with heart failure and reduced ejection fraction (HFrEF) were randomized (1:1) to receive usual care or a strategy using digital consults (DCs). DCs contained (1) digital data sharing from patient to clinician (pharmacotherapy use, home-measured vital signs and Kansas City Cardiomyopathy Questionnaires); (2) patient education via a text-based e-learning; and (3) guideline recommendations to all treating clinicians.
View Article and Find Full Text PDFArticle Synopsis
- Three types of muscular dystrophy, called dystroglycanopathies, are linked to problems in the ribitol pathway and involve specific gene mutations.
- Ribose supplementation was tested in a patient with limb girdle muscular dystrophy type 2I, showing it was well tolerated and led to significant increases in a beneficial compound (CDP-ribitol) and a decrease in muscle enzyme levels.
- Although the clinical and patient-reported outcomes didn't show objective improvements, the patient felt subjective benefits in muscle strength, fatigue, and pain, suggesting more research is needed on ribose's effects.
Aims: Many heart failure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT) despite clear benefit on morbidity and mortality outcomes. Digital consults (DCs) have the potential to improve efficiency on GDMT optimization to serve the growing HF population. The investigator-initiated ADMINISTER trial was designed as a pragmatic multicenter randomized controlled open-label trial to evaluate efficacy and safety of DC in patients on HF treatment.
View Article and Find Full Text PDF